Diagnostic Test for Uterine Cancer
(PROACTION: Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to develop a simple test to help rule out gynecological cancers in women experiencing unusual uterine bleeding or bleeding after menopause. The focus is on finding a non-invasive way to diagnose these cancers early. Ideal participants are women aged 45 and older who still have a uterus and have been experiencing these specific types of bleeding. Women dealing with these symptoms and meeting the criteria may find this trial suitable. As an unphased trial, participation offers the opportunity to contribute to groundbreaking research that could lead to early detection methods for gynecological cancers.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to uncover new insights into reproductive cancers in women, potentially leading to groundbreaking treatments. Unlike current approaches that largely focus on broad-spectrum chemotherapy and radiation, this investigation might reveal more targeted therapies. This trial could identify unique biological markers or genetic profiles that allow for personalized treatment options, significantly improving outcomes and reducing side effects. By focusing on the underlying mechanisms specific to reproductive cancers, the trial holds promise for more effective and tailored interventions in the future.
Who Is on the Research Team?
Andrea Mariani, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Test Development
Participants undergo non-invasive diagnostic testing to rule out gynecological cancer
Follow-up
Participants are monitored for safety and effectiveness after diagnostic testing
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
PinkDx, Inc.
Lead Sponsor